To Be Discontinued Tablet Psychiatry
Ramelteon Tablet · 2 active FDA presentation rows for this drug
Brand: ROZEREM
FDA lists Ramelteon Tablet as To Be Discontinued (Takeda Pharmaceuticals USA Inc.).
No availability text on this FDA row.
Ramelteon Tablet: To Be Discontinued
FDA availability text is not recorded on this row. 2 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Ramelteon Tablet
- Manufacturer
- Takeda Pharmaceuticals USA Inc.
- Dosage Form
- Tablet
- Presentation
- Rozerem, Tablet, 8 mg (NDC 64764-805-30)
- Package NDC
- 64764-805-30
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Mar 19, 2026
- Last Updated
- Mar 19, 2026
- Therapeutic Category
- Psychiatry
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Product is expected to be available through June 2027.
Full Drug Profile
ramelteon
Side effects, interactions, warnings & more
Nearby, Other Ramelteon Shortage Records
FDA reason on file: Product is expected to be available through June 2027. General shortage guidance lives on the tracker hub.